The SEC is investigating claims that Cassava Sciences, the sixth-best performing U.S. stock this year, manipulated research results of its experimental Alzheimer’s drug
Cassava Sciences, one of best-performing U.S. stocks this year, denies claims that it manipulated research results
Some images in journal articles about the efficacy of Cassava Sciences’ Alzheimer’s drug appeared to have been improperly altered, according to short sellers and some independent researchers.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen shares slide 4% after EU advisory committee says it can't agree to endorse company's Alzheimer's disease drugBiogen Inc. shares undefined slid 4% in premarket trade Wednesday, after the company said it had received a 'negative trend vote' from an advisory committee...
Read more »
Pfizer seeks FDA emergency use authorization for its experimental Covid-19 antiviral pillPfizer announced Tuesday that it is seeking emergency use authorization from the US Food and Drug Administration for its experimental antiviral Covid-19 pill, known as PF-07321332 or Paxlovid.
Read more »
Column: How the FDA's lousy judgment and a greedy drug company combined to hit Medicare members hardThe FDA approved an unproven Alzheimer's drug, and its manufacturer priced it in the stratosphere. Result: Medicare members get higher premiums.
Read more »
Pfizer asks FDA to authorize Covid antiviral pillsPfizer asked the FDA to authorize its oral Covid antiviral pill called Paxlovid. The treatment is highly effective in reducing the risk of hospitalization.
Read more »
Pfizer Seeks FDA Emergency Use Authorization for Its COVID-19 PillPfizer has signed a deal to allow other manufacturers to make its experimental COVID-19 pill, possibly opening up access to treatment to countries across the world:
Read more »
Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pillPfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill.
Read more »